Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study

INTRODUCTION: Few data exist regarding the immunogenicity of the third dose of BNT162b2 relative to the second dose in patients with inflammatory bowel disease (IBD) on different immunosuppressive therapies. We investigated the immunogenicity of BNT162b2 vaccine booster dose in patients with IBD on...

Descripción completa

Detalles Bibliográficos
Autores principales: Shehab, Mohammad, Alrashed, Fatema, Alfadhli, Ahmad, Alsayegh, Abdulwahab, Aldallal, Usama, Alsayegh, Mariam, Cherian, Preethi, Alkhair, Irina, Thanaraj, Thangavel Alphonse, Channanath, Arshad, Dashti, Ali A., Albanaw, Anwar, Ali, Hamad, Abu-Farha, Mohamed, Abubaker, Jehad, Al-Mulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289180/
https://www.ncbi.nlm.nih.gov/pubmed/35860742
http://dx.doi.org/10.3389/fmed.2022.933996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289180/
https://www.ncbi.nlm.nih.gov/pubmed/35860742
http://dx.doi.org/10.3389/fmed.2022.933996

Ejemplares similares